MAPT and Alzheimer disease: Ultimately, as gene silencing therapeutics for CNS diseases move into the clinic with greater frequency, the risk-reward calculations for this invasive therapy may improve to the point of wider deployment in patients at high risk for all diseases in which tau pathology features prominently, such as AD.